Related references
Note: Only part of the references are listed.Lopinavir-ritonavir versus hydroxychloroquine for viral clearance and clinical improvement in patients with mild to moderate coronavirus disease 2019
Ji-Won Kim et al.
KOREAN JOURNAL OF INTERNAL MEDICINE (2021)
Lopinavir/ritonavir as a third agent in the antiviral regimen for SARS-CoV-2 infection
Periklis Panagopoulos et al.
JOURNAL OF CHEMOTHERAPY (2021)
Lopinavir/ritonavir is associated with pneumonia resolution in COVID-19 patients with influenza coinfection: A retrospective matched-pair cohort study
Chong Yu et al.
JOURNAL OF MEDICAL VIROLOGY (2021)
Recent discovery and development of inhibitors targeting coronaviruses
Thanigaimalai Pillaiyar et al.
DRUG DISCOVERY TODAY (2020)
Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China
Dawei Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
Nanshan Chen et al.
LANCET (2020)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang et al.
LANCET (2020)
Clinical Characteristics of Coronavirus Disease 2019 in China
W. Guan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia
Qun Li et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province
Kui Liu et al.
CHINESE MEDICAL JOURNAL (2020)
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19
Adarsh Bhimraj et al.
CLINICAL INFECTIOUS DISEASES (2020)
Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia
Ruggero Capra et al.
EUROPEAN JOURNAL OF INTERNAL MEDICINE (2020)
Factors associated with prolonged viral shedding and impact of lopinavir/ritonavir treatment in hospitalised non-critically ill patients with SARS-CoV-2 infection
Dan Yan et al.
EUROPEAN RESPIRATORY JOURNAL (2020)
Comprehensive analysis of drugs to treat SARS-CoV-2 infection: Mechanistic insights into current COVID-19 therapies (Review)
George Mihai Nitulescu et al.
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE (2020)
Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
Sara Baldelli et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Zhen Zhu et al.
JOURNAL OF INFECTION (2020)
Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study
Lisi Deng et al.
JOURNAL OF INFECTION (2020)
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
Ivan Fan-Ngai Hung et al.
LANCET (2020)
Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases
Cynthia Liu et al.
ACS CENTRAL SCIENCE (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19
B. Cao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression
Fang Liu et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19
Zhicheng Zhang et al.
JOURNAL OF MEDICAL VIROLOGY (2020)
Efficacy and Safety of Lopinavir/Ritonavir or Arbidol in Adult Patients with Mild/Moderate COVID-19: An Exploratory Randomized Controlled Trial
Yueping Li et al.
MED (2020)
2491. Post-Exposure Prophylaxis With Ribavirin Plus Lopinavir/Ritonavir for Middle East Respiratory Syndrome in Healthcare Workers
So Yeon Park et al.
Open Forum Infectious Diseases (2018)
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset
Jasper Fuk-Woo Chan et al.
JOURNAL OF INFECTIOUS DISEASES (2015)
Screening of an FDA-Approved Compound Library Identifies Four Small-Molecule Inhibitors of Middle East Respiratory Syndrome Coronavirus Replication in Cell Culture
Adriaan H. de Wilde et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration
Alessandro Liberati et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activity
N Barretto et al.
JOURNAL OF VIROLOGY (2005)
Molecular mechanisms of severe acute respiratory syndrome (SARS)
DA Groneberg et al.
RESPIRATORY RESEARCH (2005)
Therapeutic drug monitoring of lopinavir/ritonavir given alone or with a non-nucleoside reverse transcriptase inhibitor
C Solas et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings
CM Chu et al.
THORAX (2004)
In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
F Chen et al.
JOURNAL OF CLINICAL VIROLOGY (2004)
Small molecules targeting severe acute respiratory syndrome human coronavirus
CY Wu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Share Paper
